Compare 3M Company (MMM) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs Repligen Corporation Common Stock — how do they compare? 3M Company trades at $164.99 (market cap $83.94B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: 3M Company is far larger — about 7.5× Repligen Corporation Common Stock's market cap, and 3M Company pays a 1.92% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold 3M Company for 169 Days and Repligen Corporation Common Stock for 0 Days on average.
| MMM | RGEN | |
|---|---|---|
Market Cap | $83.94B | $11.14B |
Volume | 2,547,210 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $183.79 | $194.57 |
52-Week Low | $141.10 | $102.87 |
Typical Hold Time | 169 Days | 0 Days |
Enterprise Value | $93.17B | $11.02B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $164.46, up 2.22% with strong recent earnings beats and a bullish analyst consensus price target of $191. The stock shows bearish technical signals but maintains solid fundamentals with 11.9% net margins and 82.77% ROE. Recent Q2 2026 results confirmed operational improvements with 5.4% organic growth and raised guidance, though technical indicators suggest near-term pressure.
The outlook remains positive with manageable litigation risks and strategic focus on high-growth areas like data centers. Key risks include consumer segment weakness and debt levels. Wall Street sentiment is balanced with 48% buy ratings, supporting potential upside from current levels despite technical bearishness.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
